Satralizumab

立即咨询

Satralizumab

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:	1535963-91-7
包装:	5mg
市场价:	12600元

产品介绍

Satralizumab 是一种人源化单克隆抗体，是一种有效的白细胞介素 -6 (IL-6) 抑制剂。Satralizumab 可防止褐家鼠的 dTAA 形成和发展。Satralizumab 可用于视神经脊髓炎 (NMOSD) 和降胸主动脉动脉瘤 (dTAA) 的研究。

Cas No.

1535963-91-7

储存条件

Store at -20°C

General tips

For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.

Shipping Condition

Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request

产品描述

Satralizumab, a humanized monoclonal antibody, is a potentInterleukine-6 (IL-6)inhibitor. Satralizumab prevents dTAA formation and progression in rattusnorvegicus. Satralizumab can be used for neuromyelitis optica spectrum disorder (NMOSD) and descending thoracic aorta aneurysm (dTAA) research^[1]^[2].

Satralizumab (120 mg, Subcutaneously, once every 2 weeks, for 4 weeks) prevents dTAA formation and progression in rattusnorvegicus^[1].

Animal Model:	Rattusnorvegicus(forty, male, 10-week-old, four equal groups)^[1]
Dosage:	120 mg
Administration:	Subcutaneously, once every 2 weeks, for 4 weeks
Result:	Prevented dTAA (descending thoracic aorta aneurysm) formation and progression.